{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 52299f42-3a93-476f-aa59-cd89188a7bb8 --><h2>Changes</h2><!-- end field 52299f42-3a93-476f-aa59-cd89188a7bb8 -->","summary":null,"htmlStringContent":"<!-- begin item b77818af-9f96-4c70-ae25-01dc4b2c5262 --><!-- begin field e62707c0-1a0a-4e0b-8bb5-70273a2299cd --><p><strong>March</strong><strong><strong> </strong>2019 </strong>— reviewed. A literature search was conducted in March 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to clinical recommendations have been made.</p><!-- end field e62707c0-1a0a-4e0b-8bb5-70273a2299cd --><!-- end item b77818af-9f96-4c70-ae25-01dc4b2c5262 -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7105be47-f38b-5335-b14d-69db43326579","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6dd94f89-9ea8-515c-8b98-bb256e84f984","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field f51233a7-58cc-4cbc-b7d7-9667c403dfb7 --><h3>Previous changes</h3><!-- end field f51233a7-58cc-4cbc-b7d7-9667c403dfb7 -->","summary":null,"htmlStringContent":"<!-- begin item 429876c7-5341-4029-8d82-e0f3ef226b76 --><!-- begin field 04b9a3a0-e7d8-4a8b-ade1-a19275813d5b --><p><strong>November 2018</strong> — minor update. Additions to contraindications and monitoring for desmopressin.</p><p><strong>July 2018</strong> — minor update. Anxiety has been added as an adverse effect for men taking 5-alpha reductase inhibitors.</p><p><strong>September 2017</strong> — minor update. Additions to adverse effects section for men taking 5-alpha reductase inhibitors for depression and suicidal ideation. </p><p><strong>July 2017</strong> — minor update. Additions to adverse effects section for men taking finasteride or dutasteride for prostate cancer, prostate-specific antigen (PSA), and cardiovascular events. </p><p><strong>June 2017</strong> — minor update. Addition to adverse effects section for depression and suicidal thoughts in men taking finasteride. </p><p><strong>November 2016</strong> — minor update. Following post-market surveillance, severe hypertension, dizziness, constipation, diarrhoea, headache and dizziness have been added as adverse effects [ABPI, 2016]. Following a Medicines and Healthcare products Regulatory Agency (MHRA) <em>Drug safety update</em>, severe uncontrolled hypertension has been added as a contraindication [MHRA, 2015]. </p><p><strong>February 2015 </strong>—<strong> </strong>minor update. Following post-market surveillance, angioedema has been added as a rare adverse effect of mirabegron.</p><p><strong>October 2014 </strong>— reviewed. A literature search was conducted in July 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. Changes have been made to the indications for prostate specific antigen (PSA) testing and the choice of antimuscarinics for men with overactive bladder as a predominant symptom, with mirabegron added as a new drug option.</p><p><strong>February 2014 </strong>—<strong> </strong>minor update. Update to the Prescribing Information text for tamsulosin to reflect that it should not be given with strong inhibitors of CYP3A4, in line with the manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>January 2013 </strong>— minor update. Removed the black triangle status from fesoterodine as this is no longer a black triangle drug.</p><p><strong>November 2012 </strong>—<strong> </strong>minor update. The links to the electronic medicines website (<a data-hyperlink-id=\"72991c6f-03b4-43da-a904-a93100cef003\" href=\"http://www.medicines.org.uk/\">www.medicines.org.uk</a>) have been updated.</p><p><strong>January 2012 </strong>—<strong> </strong>minor update. Added updated information from the manufacturer's SPC which states that dutasteride is contraindicated in people with hypersensitivity to soya, peanut, or any of the other excipients. Issued January 2012.</p><p><strong>May 2011 </strong>—<strong> </strong>minor update. Removed the black triangle status from desmopressin prescriptions because desmopressin is no longer a black triangle drug. Issued in June 2011.</p><p><strong>April to August 2010 </strong>—<strong> </strong>this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence. This CKS topic replaces the former topic on <em>Prostate - benign hyperplasia</em>. The scope of this topic includes that of the previous topic on <em>Prostate - benign hyperplasia</em>, and also includes the management of voiding symptoms, urinary retention, stress incontinence, overactive bladder, nocturnal polyuria, and post-voiding symptoms. With one notable exception, all the management recommendations in <em>Prostate - benign hyperplasia </em>have been included in this topic. The new recommendation is that men who continue to have storage symptoms despite treatment with an alpha blocker should be offered combination therapy with an antimuscarinic agent and an alpha blocker.</p><p><strong>December 2009 </strong>— minor update. The MHRA has recently advised that men taking finasteride should be advised to promptly report any changes in their breast tissue such as lumps, pain, or nipple discharge. Cases of breast cancer have rarely been reported. Issued in December 2009.</p><p><strong>October 2009 </strong>— minor update to the section on <em>Contraindications </em>for alpha blockers. Issued in October 2009.</p><p><strong>August 2009 </strong>— minor update. The section on <em>PSA testing </em>now includes advice on when to defer testing (for example for at least 1 week after digital rectal examination). Issued in August 2009.</p><p><strong>December 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued September 2008.</p><p><strong>February 2006 </strong>— updated to include information on saw palmetto. Issued in February 2006.</p><p><strong>June 2005 </strong>— reviewed. Validated in September 2005 and issued in November 2005.</p><p><strong>November 2002 </strong>— updated to incorporate advice on PSA testing from the NHS Prostate Cancer Risk Management Programme. Issued in December 2002.</p><p><strong>March 2002 </strong>— reviewed and updated to incorporate referral advice from the National Institute for Health and Care Excellence (NICE). Validated in March 2002 and issued in April 2002.</p><p><strong>October 2000 </strong>— updated to incorporate the Department of Health's <em>Referral guidelines for suspected urological cancer</em>.</p><!-- end field 04b9a3a0-e7d8-4a8b-ade1-a19275813d5b --><!-- end item 429876c7-5341-4029-8d82-e0f3ef226b76 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}